Joshua K. Sabari, MD

home / authors / joshua-k-sabari-md

Joshua Sabari, MD, is an assistant professor of medicine, thoracic medical oncology, Perlmutter Cancer Center NYU Langone Health.

Articles

First-Line Treatment Paradigm of NSCLC and the Advent of Immunotherapy

Joshua K. Sabari, MD

December 7th 2022

Joshua Sabari, MD, a thoracic medical oncologist at NYU Langone Health Perlmutter Cancer Center in New York, NY reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.

A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy

Joshua K. Sabari, MD

November 14th 2022

In the first installment of this series, Joshua Sabari, MD, provides an overview on the use of chemotherapy for first-line treatment of NSCLC, and discusses how the more recent availability of PD-1/PD-L1– and CTLA-4–targeted immunotherapy is changing the field.

EGFR Therapies Fail to Benefit Patients With NSCLC and Exon 20 Insertions

Joshua K. Sabari, MD

June 29th 2022

Joshua K. Sabari, MD, discusses the significance of EGFR exon 20 insertion mutations in patients with non–small cell lung cancer.

Atezolizumab and Durvalumab Show Similar Benefit for ES-SCLC

Joshua K. Sabari, MD

February 9th 2022

Joshua K. Sabari, MD, discusses the trials that showed efficacy for durvalumab and atezolizumab in patients with extensive-stage small cell lung cancer.

<1 2 3